Precision Medicine News and Updates | Precision Medicine Online
WEBResearchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease. Precision Medicine Online provides the latest news for healthcare leaders and scientists interested in precision medicine and individualized approaches to treatment and prevention.
In Brief This Week: UniQure, WHO, Vertex, Lonza, Elixirgen, Eli Lilly ...
WEB7 hours ago — The World Health Organization this week endorsed dual-stain cytology testing in its cervical cancer prevention guidelines. The only US Food and Drug Administration-approved and CE-marked dual-stain cytology test to help identify human papillomavirus-positive patients at risk of developing cervical cancer is Roche's CINtec Plus Cytology assay, Roche said in a statement.
AstraZeneca Nabs FDA Approval for Tagrisso in Stage III, …
WEB1 day ago — NEW YORK – The US Food and Drug Administration on Wednesday approved AstraZeneca's Tagrisso (osimertinib) for certain patients with stage III EGFR-mutated non-small cell lung cancer. The EGFR inhibitor is indicated for patients with tumors harboring exon 19 deletions or exon 21 (L858R) mutations ...
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer ...
WEB2 days ago — NEW YORK – The US Food and Drug Administration will ask experts in its Oncologic Drugs Advisory Committee (ODAC) on Thursday whether it should narrow two currently approved indications of checkpoint inhibitors — Merck's Keytruda (pembrolizumab) and Bristol Myers Squibb's Opdivo (nivolumab) — to patients with PD-L1-expressing gastric and gastroesophageal cancer.
Precision Oncology News - Precision Medicine Online
WEBSep 16, 2024 — Indiana University, Indiana Biosciences Research Institute Form Precision Medicine Center. Sep 19, 2024. New Multi-Cancer Detection Data Speak to Both Promises and Cautions of Blood-Based Assays. Sep 18, 2024. Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer. Sep 18, 2024.
Breaking News - Precision Medicine Online
WEB2 days ago — NIH Awards $27M for Genomics-Enabled Learning Health System Network. The agency has committed $5.4 million for the first year of the five-year program to establish a network to analyze and improve how genomic information is integrated into patient care. Sep 23, 2024.
Nomic Bio, Parker Institute for Cancer Immunotherapy Team up to …
WEB2 days ago — NEW YORK – Nomic Bio on Tuesday said it signed a collaboration agreement with the Parker Institute for Cancer Immunotherapy (PICI) to identify protein biomarkers associated with immunotherapy response among patients with various types of cancer. Using its nELISA protein quantification platform ...
Regulatory News & FDA Approvals | Precision Medicine Online
WEBBiosyngen to Begin Phase II Study of CAR T-Cell Therapy in EBV-Positive Nasopharyngeal Carcinoma. Aug 16, 2024. 'The Lead That Starts the Avalanche': Second Solid Tumor Cell Therapy Approval Energizes the Field. Read the latest regulatory headlines and FDA approvals from Precision Medicine Online.
Precision Medicine in 2023: Gene Therapies Take Center Stage …
WEBNEW YORK – 2023 was undoubtedly the year of the gene therapy in precision medicine. The US Food and Drug Administration last year approved several gene therapies that for the first time promise to treat, and even cure, rare, inherited diseases of …
Precision Oncology in 2022: New Drugs and Tests Amid Ongoing …
WEBJan 4, 2023 — NEW YORK – Looking back at 2022, plenty of new CAR T-cell, radioligand, and biomarker-defined treatments entered the market, as did new tissue and liquid biopsy tests to identify cancer patients eligible for these therapies.